Oncolytics Biotech (TSE:ONC) Trading Up 13.7%

Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Rating) traded up 13.7% during mid-day trading on Wednesday . The stock traded as high as C$2.77 and last traded at C$2.74. 158,396 shares traded hands during trading, an increase of 230% from the average session volume of 48,053 shares. The stock had previously closed at C$2.41.

Wall Street Analysts Forecast Growth

ONC has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Oncolytics Biotech in a report on Tuesday, March 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a C$9.00 price objective on shares of Oncolytics Biotech in a report on Monday, March 6th. Finally, Jonestrading set a C$9.00 price objective on Oncolytics Biotech and gave the stock a “buy” rating in a report on Wednesday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of C$6.75.

Oncolytics Biotech Trading Up 2.3 %

The company has a quick ratio of 8.86, a current ratio of 13.88 and a debt-to-equity ratio of 2.20. The company has a 50-day moving average price of C$1.87 and a 200-day moving average price of C$2.11. The company has a market capitalization of C$187.46 million, a price-to-earnings ratio of -6.96 and a beta of 1.79.

Oncolytics Biotech (TSE:ONC – Get Rating) last announced its quarterly earnings results on Friday, March 3rd. The company reported C($0.14) EPS for the quarter, missing analysts’ consensus estimates of C($0.07) by C($0.07). Research analysts predict that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

(Get Rating)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.